MannKind shares rose over 7% pre-market after the FDA approved an updated label for Afrezza inhaled insulin. The revision offers clearer starting-dose guidance for adults switching from injections or pumps, supported by clinical trial data showing improved post-meal glucose control.
Sponsored Advertisement
No comments yet. Be the first!